Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays

Canadian Journal of Physiology and Pharmacology

Volumn 75, Issue 9, 1997, Pages 1088-1095

  Riendeau, Denis ^a   Charleson, Stella ^a   Cromlish, Wanda ^a   Mancini, Joseph A ^a   Wong, Elizabeth ^a   Guay, Jocelyne ^a  

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

Author keywords

COS 2 inhibitors; Cyclooxygenase; Gastrointestinal toxicity; Nonsteroidal anti inflammatory drugs; Platelets; Prostaglandin synthase

Indexed keywords

1 (4 FLUOROPHENYL) 2 [(4 METHYLSULFONYL)PHENYL]CYCLOPENTENE; 5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE; 5 BROMO 2 (4 FLUOROPHENYL) 3 (4 METHYLSULFONYLPHENYL)THIOPHENE; 6 (2,4 DIFLUOROPHENYLTHIO) 5 METHANESULFONAMIDO 1 INDANONE; ARACHIDONIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETODOLAC; FLOSULIDE; FLUNIXIN; FLURBIPROFEN; IGURATIMOD; INDOMETACIN; MELOXICAM; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PIROXICAM; PROSTAGLANDIN E2; RS 57067; SALICYLIC ACID; SC 58451; SULINDAC SULFIDE; THROMBOXANE B2; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARACHIDONIC ACID METABOLISM; ARTICLE; ASSAY; CELL LINE; CHO CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; ENZYME INHIBITION; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; MICROSOME; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE;

EID: 0030733305     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/y97-130     Document Type: Article

References (53)

1. Allison, M.C., Howatson, A.G., Torrance, C.J., Lee, F.D., and Russell, R.I. 1992. Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. New Engl. J. Med. 327: 749-754.
2. Appleyard, C.B., McCafferty, D.-M., Tigley, A.W., Swain, M.G., and Wallace, J.L. 1996. Tumor necrosis factor mediation of NSAID-induced gastric damage: role of leucocyte adherence. Am. J. Physiol. 270: G42-G48.
3. Argentieri, D.C., Ritchie, D.M., Ferro, M.P., Kirchner, T., Wachter, M.P., Anderson, D.W., Rosenthale, M.E., and Capetola, R.J. 1994. Tepoxalin: a dual cyclooxygenase/5-lipoxygenase inhibitor of arachidonic acid metabolism with potent anti-inflammatory activity and a favorable gastrointestinal profile. J. Pharmacol. Exp. Ther. 271: 1399-1408.
4. Bakhle, Y.S., and Botting, R.M. 1996. Cyclooxygenase-2 and its regulation in inflammation. Mediators Inflammation, 5: 305-323.
5. Barnett, J.W., Dunn, J.P., Kertesz, D.J., Miller, A.B., Morgans, D.J., Ramesha, C.S., Sigal, C.E., Sjogren, E.B., Smith, D.B., Talamas, F.X., Sigal, E.C., and Morgans, D. 1996. Eur. Patent-714895.
6. Battistini, B., Botting, R., and Bakhle, Y.S. 1994. COX-1 and COX-2: toward the development of more selective NSAIDs. Drug News Perspect. 7: 501-512.
7. Bennett, A., and Tavares, I.A. 1995. NSAIDs, COX-2 inhibitors, and the gut. Lancet, 346: 1105.
8. Blower, P.R. 1992. The unique pharmacologic profile of nabumetone. J. Rheumatol. 19(Suppl. 36): 13-19.
9. Boughton-Smith, N.K., and Whittle, B.J.R. 1983. Stimulation and inhibition of prostacyclin formation in the gastric mucosa and ileum in vitro by anti-inflammatory agents. Br. J. Pharmacol. 78: 173-180.
10. Champion, G.D., Feng, P.H., Azuma, T., Caughey, D.E., Chan, K.H., Kashiwazaki, S., Liu, H.-C., Nasution, A.R., Nobunaga, M., Prichanond, S., Torralba, T.P., Udom, V., Utis, D., Wang, S.R., Wong, W.S., Yang, D.-J., and Yoo, M.C. 1997. NSAID-induced gastrointestinal damage. Drugs, 53: 6-19.
11. Chan, C.-C., Boyce, S., Brideau, C., Ford-Hutchinson, A.W., Gordon, R., Guay, D., Hill, R.G., Li, C.-S., Mancini, J., Penneton, M., Prasit, P., Rasori, R., Riendeau, D., Roy, P., Tagari, P., Vickers, P., Wong, E., and Rodger, I.W. 1995. Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J. Pharmacol. Exp. Ther. 274: 1531-1537.
12. Copeland, R.A., Williams, J.M., Giannaras, J., Nurnberg, S., Covington, M., Pinto, D., Pick, S., and Trzaskos, J.M. 1994. Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase. Proc. Natl. Acad. Sci. U.S.A. 91: 11 202-11 206.
13. Doyle, M.J., Nemeth, P.R., Skoglund, M.L., and Mandel, K.G. 1989. In vivo assessment of precursor induced prostaglandin release within the rat gastric lumen. Prostaglandins, 38: 581-597.
14. Ehrich, E., Mehlisch, D., Perkins, S., Brown, P., Wittreich, J., Lipschutz, K., and Gertz, B. 1996. Efficacy of MK-966, a highly selective inhibitor of COX-2, in the treatment of postoperative dental pain. Arthritis Rheum. 39(Suppl. 9): S81.
15. Engelhardt, G., Homma, D., Schlegel, K., Utzmann, R., and Schnitzler, C. 1995. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm. Res. 44: 423-433.
16. Engelhardt, G., Bogel, R., Schnitzer, C., and Utzmann, R. 1996. Meloxicam: influence on arachidonic acid metabolism. Part 1. In Vitro findings. Biochem. Pharmacol. 51: 21-28.
17. 2 production in minced intestinal tissue. Arch. Int. Pharmacodyn. Ther. 316: 114-123.
18. Futaki, N., Takahashi, S., Yokoyama, M., Arai, I., Higuchi, S., and Otomo, S. 1994. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins, 47: 55-59.
19. Gans, K.R., Galbraith, W., Roman, R.J., Haber, S.B., Kerr, J.S., Schmidt, W.K., Smith, C., Hewes, W.E., and Ackerman, N.R. 1990. Anti-inflammatory and safety profile of DuP 697, a novel orally effective prostaglandin synthesis inhibitor. J. Pharmacol. Exp. Ther. 254: 180-187.
20. Gierse, J.K., Hauser, S.D., Creely, D.P., Koboldt, C., Rangwala, S.H., Isakson, P.C., and Seibert, K. 1995. Expression and selective inhibition of the constitutive and inducible forms of human cyclooxygenase. Biochem. J. 305: 479-484.
21. Griswold, D.E., and Adams, J.L. 1996. Constitutive cyclooxygenase (COX-1) and inducible cyclooxygenase (COX-2): rationale for selective inhibition and progress to date. Med. Res. Rev. 16: 181-206.
22. Grossmann, C.J., Wiseman, J., Lucas, F.S., Trevethick, M.A., and Birch, P.J. 1995. Inhibition of constitutive and inducible cyclooxygenase activity in human platelets and mononuclear cells by NSAIDs and COX 2 inhibitors. Inflamm. Res. 44: 253-257.
23. Hayllar, J., and Bjarnason, I. 1995. NSAIDs, COX-2 inhibitors, and the gut. Lancet, 346: 1629.
24. Herschman, H.R. 1996. Prostaglandin synthase 2. Biochim. Biophys. Acta, 1299: 125-140.
25. Hubbard, R.C., Koepp, R.J., Yu, S., Talwalker, S., Geis, G.S., Wiesenhutter, C.W., Makarowski, W.S., and Paulus, H.A. 1996. SC-58635 (Celecoxib), a novel COX-2 selective inhibitor, is effective as a treatment for osteoarthritis (OA) in a short-term pilot study. Arthritis Rheum. 39 (Suppl. 9): S226.
26. Hudson, N., Hawthorne, A.B., Cole, A.T., Jones, P.D.E., and Hawkey, C.J. 1992. Mechanisms of gastric and duodenal damage and protection. Hepatogastroenterol. 39(Suppl. 1): 31-36.
27. Kargman, S., Charleson, S., Cartwright, M., Frank, J., Riendeau, D., Mancini, J., Evans, J., and O'Neill, G. 1996a. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology, 111: 445-454.
28. Kargman, S., Wong, E., Greig, G.M., Falgueyret, J.-P., Cromlish, W., Ethier, D., Yergey, J.A., Riendeau, D., Evans, J.F., Kennedy, B., Tagari, P., Francis, D.A., and O'Neill, G.P. 19966. Mechanism of selective inhibition of human prostaglandin G/H synthase-1 and -2 in intact cells. Biochem. Pharmacol. 52: 1113-1125.
29. Klein, T., Nusing, R.M., Pfeilschifter, J., and Ullrich, V. 1994. Selective inhibition of cyclooxygenase 2. Biochem. Pharmacol. 48: 1605-1610.
30. Laneuville, O., Breuer, D.K., DeWitt, D.L., Hla, T., Funk, C.D., and Smith, W.L. 1995. Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J. Pharmacol. Exp. Ther. 271: 927-934.
31. Langenbach, R., Morham, S.G., Tiano, H.F., Loftin, C.D., Ghanayem, B.I., Chulada, P.C., Mahler, J.F., Lee, C.A., Goulding, E.H., Kluckman, K.D., Kim, H.S., and Smities, O. 1995. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell, 83: 483-492.
32. Langman, M.J.S., Weil, J., Wainwright, P., Lawson, D.H., Rawlins, M.D., Logan, R.F.A., Murphy, M., Vessey, M.P., and Colin-Jones, D.G. 1994. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet, 343: 1075-1078.
33. Laporte, J.-R., Carne, X., Vidal, X., Moreno, V., and Juan, J. 1991. Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs. Lancet, 337: 85-89.
34. Leblanc, Y., Gauthier, J.Y., Ethier, D., Guay, J., Mancini, J., Riendeau, D., Tagari, P., Vickers, P., Wong, E., and Prasit, P. 1995. Synthesis and biological evaluation of 2,3-diarylthiophenes as selective COX-2 and COX-1 inhibitors. Bioorg. Med. Chem. Lett. 5: 2123-2128.
35. Masferrer, J.L., Zweifel, B.S., Manning, P.T., Hauser, S.D., Leahy, K.M., Smith, W.G., Isakson, P.C., and Seibert, K. 1994. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc. Natl. Acad. Sci. U.S.A. 91:3228-3232.
36. Melarange, R., Gentry, C., Blower, P.R., Toseland, C.D.N., and Spangler, R. 1995. Nabumetone, in contrast to etodolac, lacks gastrointestinal irritancy in the rat: assessment by the inflammatory marker, haptoglobin, and blood loss. Inflammopharmacology, 3: 259-270.
37. Moore, P.F., Larson, D.L., Otterness, I.G., Weissman, A., Kadin, S.B., Sweeney, F.J., Eskra, J.D., Nagahisa, A., Sakakibara, M., and Carty, T.J. 1996. Tenidap, a structurally novel drug for the treatment of arthritis: antiinfiammatory and analgesic properties. Inflamm. Res. 45: 54-61.
38. O'Neill, G.P., Mancini, J.A., Kargman, S., Yergey, J., Kwan, M.Y., Falgueyret, J.-P., Abramovitz, M., Kennedy, B.P., Ouellet, M., Cromlish, W., Culp, S., Evans, J.F., Ford-Hutchinson, A.W., and Vickers, P.J. 1994. Overexpression of human prostaglandin G/H synthase-1 and -2 by recombinant vaccinia virus: inhibition by nonsteroidal anti-inflammatory drugs and biosynthesis of 15-hydroxyeicosatetraenoic acid. Mol. Pharmacol. 45: 245-254.
39. Ouellet, M., and Percival, M.D. 1995. Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem. J. 306: 247-251.
40. Polisson, R. 1996. Nonsteroidal anti-inflammatory drugs: practical and theoretical considerations in their selection. Am. J. Med. 100: 31S-36S.
41. Preclik, G., Stange, E.F., and Ditschuneit, H. 1992. Limited utilization of exogenous arachidonic acid by the prostaglandin cyclooxygenase in gastric mucosa: the role of protein binding, glutathione peroxidase, and hydrogen peroxides. Prostaglandins, 44: 177-197.
42. Rainsford, K.D. 1992. Mechanisms of NSAID-induced ulcerogenesis: structural properties of drugs, focus on the micro vascular factors, and novel approaches for gastro-intestinal protection. Acta Physiol. Hungarica, 80: 23-38.
43. Reitz, D.B., Li, J.J., Norton, M.B., Reinhard, E.J., Collins, J.T., Anderson, G.D., Gregory, S.A., Koboldt, C.M., Perkins, W.E., Seibert, K., and Isakson, P.C. 1994. Selective cyclooxygenase inhibitors: novel 1,2-diarylcyclopentenes are potent and orally active COX-2 inhibitors. J. Med. Chem. 37: 3878-3881.
44. Reitz, D.B., Huang, H.-C., Li, J.J., Garland, D.J., Manning, R.E., Anderson, G.D., Gregory, S.A., Kobolt, C.M., Perkins, W.E., Seibert, K., and Isakson, P.C. 1995. Selective cyclooxygenase inhibitors: novel 4-spiro 1,2-diarylcyclopentenes are potent and orally active COX-2 inhibitors. Bioorg. Med. Chem. Lett. 5: 867-872.
45. Riendeau, D., Percival, M.D., Boyce, S., Brideau, C., Charleson, S., Cromlish, W., Ethier, D., Evans, J., Falgueyret, J.-P., Ford-Hutchinson, A.W., Gordon, R., Greig, G., Gresser, M., Guay, J., Kargman, S., Leger, S., Mancini, J.A., O'Neill, G., Ouellet, M., Rodger, I.W., Therien, M., Wang, Z., Webb, J.K., Wong, E., Xu, L., Young, R.N., Zamboni, R., Prasit, P., and Chan, C.-C. 1997. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br. J. Pharmacol. 121: 105-117.
46. Seibert, K., Zhang, Y., Leahy, K., Hauser, S., Masferrer, J., Perkins, W., Lee, L., and Isakson, P. 1994. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc. Natl. Acad. Sci. U.S.A. 91: 12 013-12 017.
47. Tanaka, K., Kawasaki, H., Kurata, K., Aikawa, Y., Tsukamoto, Y., and Inaba, T. 1995. T-614, a novel antirheumatic drug, inhibits both the activity and induction of cyclooxygenase-2 (COX-2) in cultured fibroblasts. Jpn. J. Pharmacol. 67: 305-314.
48. Traversa, G., Walker, A.M., Ippolito, F.M., Caffari, B., Capurso, L., Dezi, A., Koch, M., Maggini, M., Alegiani, S.S., and Raschetti, R. 1995. Gastroduodenal toxicity of different nonsteroidal antiinflammatory drugs. Epidemiology, 6: 49-54.
49. Vane, J.R., and Botting, R.M. 1995. New insights into the mode of action of anti-inflammatory drugs. Inflamm. Res. 44: 1-10.
50. Wallace, J.L. 1994. The 1994 Merck Frosst Award. Mechanisms of nonsteroidal anti-inflammatory drug (NSAID) induced gastrointestinal damage - potential for development of gastrointestinal tract safe NSAIDs. Can. J. Physiol. Pharmacol. 72: 1493-1498.
51. Whittle, B.J.R. 1992. Unwanted effects of aspirin and related agents on the gastrointestinal tract. In Aspirin and other salicylates. Edited by J.R. Vane and R.M. Botting. Chapman and Hall Medical, London, pp. 465-509.
52. Wiesenberg-Bottcher, I., Schweizer, A., Green, J.R., Seltenmeyer, Y., and Muller, K. 1989. The pharmacological profile of CGP 28238, a highly potent anti-inflammatory compound. Agents Actions, 26: 240-242.
53. Wong, E., DeLuca, C., Boily, C., Charleson, S., Cromlish, W., Denis, D., Kargman, S., Kennedy, B.P., Ouellet, M., Skorey, K., O'Neill, G.P., Vickers, P.J., and Riendeau, D. 1997. Characterization of autocrine inducible prostaglandin H synthase-2 (PGHS-2) in human osteosarcoma cells. Inflamm. Res. 46: 51-59.